Correction: Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression (Clinical Cancer Research (2017) 23 (3721–3733) DOI: 10.1158/1078-0432.CCR-16-2726);Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression

Clinical Cancer Research

Volumn 23, Issue 14, 2017, Pages 3721-3733

  Baglio, Serena Rubina ^a   Lagerweij, Tonny ^a   Pérez Lanzón, Maria ^a   Ho, Xuan Dung ^b,c   Léveillé, Nicolas ^d   Melo, Sonia A ^e   Cleton Jansen, Anne Marie ^f   Jordanova, Ekaterina S ^g   Roncuzzi, Laura ^h   Greco, Michelina ^h   Van Eijndhoven, Monique A J ^a   Grisendi, Giulia ⁱ   Dominici, Massimo ⁱ   Bonafede, Roberta ^a,j   Lougheed, Sinead M ^a   De Gruijl, Tanja D ^a   Zini, Nicoletta ^h,k   Cervo, Silvia ^l   Steffan, Agostino ^l   Canzonieri, Vincenzo ^l   Martson, Aare ^b,m   Maasalu, Katre ^b,m   Köks, Sulev ^b,n   Wurdinger, Tom ^a,o   Baldini, Nicola ^h,p   Pegtel, D Michiel ^a   more..

^a University of Amsterdam   (Netherlands)

^b UNIVERSITY OF TARTU   (Estonia)

^c HUE UNIVERSITY   (Viet Nam)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF PORTO   (Portugal)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j UNIVERSITY OF VERONA   (Italy)

^k CNR   (Italy)

^l CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^m TARTU UNIVERSITY HOSPITAL   (Estonia)

ⁿ ESTONIAN UNIVERSITY OF LIFE SCIENCES   (Estonia)

^o MASSACHUSETTS GENERAL HOSPITAL   (United States)

^p UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; STAT3 PROTEIN; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ISOLATION; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG TARGETING; EXOSOME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RNA SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MALE; MESENCHYMAL STROMA CELL; PATHOLOGY; SECONDARY; SECRETION (PROCESS); TISSUE MICROARRAY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EXTRACELLULAR VESICLES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MESENCHYMAL STROMAL CELLS; MICE; OSTEOSARCOMA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 85024115637     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-3198     Document Type: Erratum

References (61)

1. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Osteosarcoma. J Am Acad Orthop Surg 2009;17:515–27.
2. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer 2014;14:722–35.
3. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27–40.
4. Rubio R, Abarrategi A, Garcia-Castro J, Martinez-Cruzado L, Suarez C, Tornin J, et al. Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells. Stem Cells 2014;32: 1136–48.
5. Alfranca A, Martinez-Cruzado L, Tornin J, Abarrategi A, Amaral T, de Alava E, et al. Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci 2015;72:3097–113.
6. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009;152:3–13.
7. Longhi A, Pasini A, Cicognani A, Baronio F, Pellacani A, Baldini N, et al. Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol 2005;27:314–8.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;646–74.
9. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557–63.
10. Behnan J, Isakson P, Joel M, Cilio C, Langmoen IA, Vik-Mo EO, et al. Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression. Stem Cells 2014;32:1110–23.
11. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Onoyama M, Ohnishi M, et al. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Int J Cancer 2012;132:813–23.
12. Xu W, Bian Z, Fan Q, Li G, Tang T. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett 2009;281:32–41.
13. Barcellos-de-Souza P, Gori V, Bambi F, Chiarugi P. Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim Biophys Acta 2013;1836:321–35.
14. Luo J, Ok Lee S, Liang L, Huang C-K, Li L, Wen S, et al. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 2013;33:2768–78.
15. Huang W-H, Chang M-C, Tsai K-S, Hung M-C, Chen H-L, Hung S-C. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 2013;32:4343–54.
16. Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013;4:1795.
17. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008;319:1244–7.
18. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, etal. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10:1470–6.
19. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A 2016;113:E968–77.
20. Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18:883–91.
21. Zomer A, Maynard C, Verweij FJ, Kamermans A, Schäfer R, Beerling E, et al. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell 2015;161:1046–57.
22. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012;31:3513–23.
23. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin J-P, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010;120:457–71.
24. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015;523:177–82.
25. Shao H, Chung J, Lee K, Balaj L, Min C, Carter BS, et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun 2015;6:6999.
26. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009; 219:294–305.
27. Baranski Z, Booij TH, Cleton-Jansen A-M, Price LS, van de Water B, Bovée JVMG, et al. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. J Pathol 2015;236:348–59.
28. Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Pérez Lanzón M, Zini N, et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther 2015;6:127.
29. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 2010;70:3718–29.
30. van Eijndhoven MAJ, Zijlstra JM, Groenewegen NJ, Drees EEE, van Niele S, Baglio SR, et al. Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients. JCI Insight 2016;1: e89631.
31. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:550.
32. Baglio SR, van Eijndhoven MAJ, Koppers-Lalic D, Berenguer J, Lougheed SM, Gibbs S, et al. Sensing of latent EBV infection through exosomal transfer of 50pppRNA. Proc Natl Acad Sci U S A 2016;113: E587–9.
33. Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 2016;352:242–6.
34. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650–9.
35. Reagan MR, Kaplan DL. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells 2011; 29:920–7.
36. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013;13:392–402.
37. Pricola KL, Kuhn NZ, Haleem-Smith H, Song Y, Tuan RS. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem 2009;108:577–88.
38. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012;109:E2110–6.
39. Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 2014;159:499–513.
40. Cossetti C, Iraci N, Mercer TR, Leonardi T, Alpi E, Drago D, et al. Extracellular vesicles from neural stem cells transfer IFN-g via Ifngr1 to activate Stat1 signaling in target cells. Mol Cell 2014;56:193–204.
41. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-b1. Haematologica 2011;96:1302–9.
42. Zhang H-G, Liu C, Su K, Su K, Yu S, Zhang L, et al. A membrane form of TNF-alpha presented by exosomes delays T-cell activation-induced cell death. J Immunol 2006;176:7385–93.
43. Seelenmeyer C, Stegmayer C, Nickel W. Unconventional secretion of fibroblast growth factor 2 and galectin-1 does not require shedding of plasma membrane-derived vesicles. FEBS Lett 2008;582:1362–8.
44. Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 2010;70: 9621–30.
45. Franchi A, Arganini L, Baroni G, Calzolari A, Capanna R, Campanacci D, et al. Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas. J Pathol. 1998;185:284–9
46. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Expression of transforming growth factor-beta (TGF-beta) receptors, TGF-beta 1 and TGF-beta 2 production and autocrine growth control in osteosarcoma cells. Int J Cancer 1994;58:440–5.
47. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14:736–46.
48. Kuijjer ML, Hogendoorn PCW, Cleton-Jansen A-M. Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor. Int J Cancer 2013;133:2512–21.
49. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta/ Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001;276: 17058–62.
50. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 2015;17:816–26.
51. Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature 2015;527:329–35.
52. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang W-C, et al. Micro-environment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 2015;527:100–4.
53. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693–706.
54. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012;38:904–10.
55. Xiao H, Chen L, Luo G, Son H, Prectoni JH, Zheng W. Effect of the cytokine levels in serum on osteosarcoma. Tumour Biol 2014;35:1023–8.
56. Rutkowski P, Kamin´ ska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003;84:151–9.
57. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009; 19:89–102.
58. Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;47:320–9.
59. Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R, et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 2015;34:290–302.
60. Rossi J-F, Lu Z-Y, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res 2015;21:1248–57.
61. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, et al. Targeting the TGFb pathway for cancer therapy. Pharmacol Ther 2015;147:22–31.